Literature DB >> 2301442

Mortality resulting from blood dyscrasias in the United States, 1984.

L K Hine1, B B Gerstman, R P Wise, Y Tsong.   

Abstract

Blood dyscrasias are rare but serious diseases. We used national death certificate data for the year 1984 to estimate the number and rate of deaths caused by four blood dyscrasias. These diseases contributed to 4,490 deaths, corresponding to a mortality rate of 18.9 per million United States population. Aplastic anemia was the most frequent cause of death, followed by thrombocytopenia, agranulocytosis, and hemolytic anemia. Mortality rates varied by age, with a small peak in young children, lower rates for ages five through 34 years, and exponentially increasing rates beyond 35 years of age. Although drug relatedness could not be reliably ascertained from our data, other surveys have estimated that approximately 30% of fatal blood dyscrasias are caused by therapeutic drugs. Assuming that 30% drug attribution also applies to the U.S. population as a whole, approximately 1,350 blood dyscrasia deaths in the U.S. in 1984 may have been caused by drugs.

Entities:  

Mesh:

Year:  1990        PMID: 2301442     DOI: 10.1016/0002-9343(90)90465-p

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  2 in total

1.  Use of gel microcolumn assay for the detection of drug-induced positive direct antiglobulin tests.

Authors:  M C Z Novaretti; C R Sopeleti; P E Dorlhiac-Llacer; D A F Chamone
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  Incidence and risk factors for agranulocytosis in Latin American countries--the Latin Study: a multicenter study.

Authors:  Nelson Hamerschlak; Eliane Maluf; Alexandre Biasi Cavalcanti; Alvaro Avezum Júnior; José Eluf-Neto; Roberto Passeto Falcão; Irene Gyongyvér Heidemarie Lorand-Metze; Daniel Goldenberg; Cézar Leite Santana; Daniela de Oliveira Werneck Rodrigues; Leny Nascimento da Motta Passos; Erika Oliveira de Miranda Coelho; Maria Carolina Tostes Pintão; Hélio Moraes de Souza; José Rafael Borbolla; Ricardo Pasquini
Journal:  Eur J Clin Pharmacol       Date:  2008-06-26       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.